Powered by

Allergan's Kythera purchase shifts focus to other aesthetic product makers

Jun 18, 2015 - The Deal Pipeline

Allergan plc's (AGN) $2.1 billion buy of aesthetic medicine company Kythera Biopharmaceuticals Inc. (KYTH) could shift the focus to smaller-cap aesthetic product producers. "We see ... the just announced [Allergan-Kythera deal] as an overall positive for our small-cap aesthetics coverage," Leerink Partners LLC director Richard Newitter wrote in a note Wednesday, adding that the deal could elevate the takeout prospects of Zeltiq Aesthetics Inc. (ZLTQ) of Pleasanton, Calif., Israel's Syneron Me...